drugset / Trial / NCT02855086
Cetuximab-IRDye 800CW in Detecting Tumors in Patients With Malignant Glioma Undergoing Surgery
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
This study is a phase 1-2 trial that evaluates the best dose of cetuximab-IRDye 800CW and how well it works in detecting tumors in patients with malignant glioma who are undergoing surgery. Cetuximab-IRDye 800CW is an optical imaging agent that may help detect tumor cells when a special camera is used.
Timeline
- Start
- 2016-10
- Primary completion
- 2016-11-08
- Completion
- 2016-11-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab-IRDye800 | Monoclonal antibody | 50 mg | Intravenous |
| Subject | Cetuximab-IRDye800 | Monoclonal antibody | 100 mg | Intravenous |
| Background | Cetuximab | Monoclonal antibody | — | Intravenous |